Brind.

Indivior, Addex Therapeutics, and Johnson & Johnson completed IND-enabling studies for substance use disorders and regained rights to the mGluR2 program.

1 report, 0 independent Updated Jun 20

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Indivior Addex Therapeutics Johnson & Johnson

Keep exploring

The entities involved

Indivior
specialty pharmaceuticals business headquartered in Richmond, Virginia
- Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.Mon 06:10
- Addex Therapeutics and Indivior are partnering on a drug candidate.Fri 07:58
Addex Therapeutics
Swiss public company

Nothing else this week.
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04

Coverage

Newest first; wire copies grouped

Jun 20Unknown outlet